Physician profile
David Alonzo
NPI 1558689901
$6,132.05
in general payments reported to CMS, 2019-2025
19 companies · $4,588 in 2025
The $4,588 reported for 2025 was more than what 90% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $469 · 2020: $237 · 2021: $30.51 · 2022: $185 · 2023: $185 · 2024: $438 · 2025: $4,588.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $4,120 · Food and Beverage: $736 · Travel and Lodging: $355.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $4,120.43 |
| Food and Beverage | $735.64 |
| Travel and Lodging | $354.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $4,533.90 | 2019-2025 | |
| Astellas Pharma US INC | $273.06 | 2019-2024 | |
| Medtronic, INC. | $211.51 | 2023-2024 | Interstim |
| Urogen Pharma, INC. | $176.08 | 2024-2025 | |
| Janssen Biotech, INC. | $142.23 | 2019-2024 | Erleada |
| Boston Scientific Corporation | $132.20 | 2019-2024 | Spaceoar Vue System - 10ml |
| Mimedx Group, INC. | $114.70 | 2024 | |
| Coloplast Corp | $87.41 | 2020-2024 | |
| Baxter Healthcare | $72.70 | 2019-2022 | |
| Abbvie INC. | $70.42 | 2024-2025 | |
| Sumitomo Pharma America, INC. | $68.44 | 2023-2025 | Orgovyx, Gemtesa |
| Amgen INC. | $65.79 | 2019-2020 | |
| Myovant Sciences INC. | $46.05 | 2021-2022 | |
| Ferring Pharmaceuticals INC. | $39.50 | 2025 | Adstiladrin |
| Bayer Healthcare Pharmaceuticals INC. | $32.03 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dendreon Pharmaceuticals LLC | $20.79 | 2019 | |
| Myriad Genetic Laboratories, INC. | $16.46 | 2024 | Prolaris |
| Tolmar Pharmaceuticals, INC. | $15.80 | 2019 | |
| Urovant Sciences INC | $12.98 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Alonzo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.